A new vaccine against the corona virus for those who have suppressed the immune system has arrived in Israel, but with priority:
organ transplants claim discrimination in the criteria for receiving the passive vaccine for the corona "Abuschild", because the vaccine is given to lung transplant recipients but not to other organ transplant recipients.
These days, the health funds are starting to give the eligible insureds the passive vaccine for corona.
It is a vaccine that contains antibodies and is intended for defined groups of patients who do not develop antibodies in response to a "regular" vaccine.
Although the passive vaccine contains the antibodies and provides protection for about six months against both infection and serious illness, the Ministry of Health guidelines stipulate that those who receive the vaccine will only be lung transplants (along with patients with other diseases such as bone marrow transplants) and other organ transplants will not be eligible. For treatment.
PM Bennett on Omicron: "We are preparing for stabilization" // Photo: GPO
Prof. Avraham Golan from the Association of Liver Transplanters: "We have finally been informed that the passive vaccine has been brought to Israel. By taking it, we are suppressed the vaccine and all organ transplant recipients can also return to an almost normal life. Get it now. We ask decision makers why there is not enough EVUSHELD in Israel and whether our lives are worth less than others. ".
Prof. Dror Mevorach, director of the corona department at Hadassah, noted in this context that "this is a very important step. Several thousand rations arrived and therefore priorities were set for the arrival of additional rations in probably a month. However, it was very important to include kidney transplants "Patients with renal insufficiency represent a large portion of the transplant population."
The Corona Virus Information Center said: "The priority for EVUSHELD beneficiaries has been set by a professional committee on the epidemiological team (ZTM) in consultation with leading doctors in the fields of hemato-oncology and transplants.
In general, the first priority for receiving the drug was given to patients whose underlying disease or drug treatment involved significantly impaired the immune system's ability to respond to the active vaccine, which is given to the general population and therefore the first priority group does not cover all immunocompromised patients.
Were we wrong?
Fixed!
If you found an error in the article, we'll be happy for you to share it with us